Accès ouvert déclaré
2023
article
Proteogenomic insights suggest druggable pathways in endometrial carcinoma
Yongchao Dou, Lizabeth Katsnelson, Yingwei Hu, Boris Reva, Runyu Hong, Yi-Ting Wang, Iga Kołodziejczak, Rita Jui-Hsien Lu, Chia‐Feng Tsai, Wen Bu, Wenke Liu, Xiaofang Guo, Eunkyung An, Rebecca C. Arend, Jasmin Bavarva, Lijun Chen, Rosalie Chu, Andrzej Czekański, Teresa Davoli, Elizabeth G. Demicco, Deborah F. DeLair, Kelly A. Devereaux, Saravana M. Dhanasekaran, Peter R. Dottino, Bailee Dover, Thomas Fillmore, McKenzie E. Foxall, Catherine Hermann, Tara Hiltke, Galen Hostetter, Marcin Jędryka, Scott D. Jewell, Isabelle Johnson, Andrea G. Kahn, Amy T. Ku, Chandan Kumar‐Sinha, Paweł Kurzawa, Alexander J. Lazar, Rossana Lazcano, Jonathan T. Lei, Yi Li, Yuxing Liao, T. Mamie Lih, Tai‐Tu Lin, John A. Martignetti, Ramya P. Masand, Rafał Matkowski, Wilson McKerrow, Mehdi Mesri, Matthew Monroe, Jamie Moon, Ronald Moore, Michael Nestor, Chelsea J. Newton, Tatiana Omelchenko, Gilbert S. Omenn, Samuel Payne, Vladislav Petyuk, Ana I. Robles, Henry Rodriguez, Kelly V. Ruggles, Dmitry Rykunov, Sara R. Savage, Athena Schepmoes, Tujin Shi, Zhiao Shi, Jimin Tan, Mason D. Taylor, Mathangi Thiagarajan, Joshua M. Wang, Karl Weitz, Bo Wen, Claire Williams, Yige Wu, Matthew A. Wyczalkowski, Xinpei Yi, Xu Zhang, Rui Zhao, David G. Mutch, Arul M. Chinnaiyan, Richard Smith, Alexey I. Nesvizhskii, Pei Wang, Maciej Wiznerowicz, Li Ding, D.R. Mani, Hui Zhang, Matthew L. Anderson, Karin Rodland, Bing Zhang, Tao Liu, David Fenyö, Andrzej Antczak, Meenakshi Anurag, Thomas Bauer, Chet Birger, Michael J. Birrer, Melissa Borucki, Shuang Cai, Anna Calinawan, Steven A. Carr, Patricia Castro, Sandra Cerda, Daniel W. Chan, David Chesla, Marcin Cieślik, Sandra Cottingham, Rajiv Dhir, Marcin J. Domagalski, Brian Druker, Elizabeth R. Duffy, Nathan Edwards, Robert A. Edwards, Matthew J. Ellis, Jennifer Eschbacher, Mina Fam, Brenda Fevrier-Sullivan, Jesse Francis, John Freymann, Stacey Gabriel, Gad Getz, Michael A. Gillette, Andrew K. Godwin, Charles A. Goldthwaite, Pamela Grady, Jason Hafron, Pushpa Hariharan, Barbara Hindenach, Katherine A. Hoadley, Jasmine Huang, Michael Ittmann, Ashlie Johnson, Corbin D. Jones, Karen A. Ketchum, Justin Kirby, Toan Le, Avi Ma’ayan, Rashna Madan, Sailaja Mareedu, Peter B. McGarvey, Francesmary Modugno, Rebecca Montgomery, Kristen Nyce, Amanda G. Paulovich, Barbara L. Pruetz, Liqun Qi, Shannon Richey, Eric E. Schadt, Yvonne Shutack, Shilpi Singh, Michael Smith, Darlene Tansil, Ratna R. Thangudu, Matt Tobin, Ki Sung Um, Negin Vatanian, Alex Webster, George D. Wilson, Jason N. Wright, Kakhaber Zaalishvili, Zhen Zhang, Grace Zhao
55Citations signalées — pas une note de qualité
35Institutions déclarées
3Pays d’affiliation déclarés
Résumé fourni par la source
We characterized a prospective endometrial carcinoma (EC) cohort containing 138 tumors and 20 enriched normal tissues using 10 different omics platforms. Targeted quantitation of two peptides can predict antigen processing and presentation machinery activity, and may inform patient selection for immunotherapy. Association analysis between MYC activity and metformin treatment in both patients and cell lines suggests a potential role for metformin treatment in non-diabetic patients with elevated MYC activity. PIK3R1 in-frame indels are associated with elevated AKT phosphorylation and increased sensitivity to AKT inhibitors. CTNNB1 hotspot mutations are concentrated near phosphorylation sites mediating pS45-induced degradation of β-catenin, which may render Wnt-FZD antagonists ineffective. Deep learning accurately predicts EC subtypes and mutations from histopathology images, which may be useful for rapid diagnosis. Overall, this study identified molecular and imaging markers that can be further investigated to guide patient stratification for more precise treatment of EC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Proteogenomic insights suggest druggable pathways in endometrial carcinoma
- Date Crossref
- 01/09/2023
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
PI3K/AKT/mTOR signaling in cancerCancer Genomics and DiagnosticsCancer-related Molecular Pathways